FDA scraps biosimilars draft guidance

In an effort to reduce the cost and increase the efficiency of biosimilars development, FDA Thursday withdrew draft guidance on statistical approaches for evaluating analytical similarities between a proposed biosimilar and its

Read the full 322 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE